Abstract The BRMS1 metastasis suppressor was recently shown to negatively regulate NF-jB signaling and down regulate NF-jB-dependent uPA expression. Here we confirm that BRMS1 expression correlates with reduced NF-jB DNA binding activity in independently derived human melanoma C8161.9 cells stably expressing BRMS1. We show that knockdown of BRMS1 expression in these cells using small interfering RNA (siRNA) leads to the reactivation of NF-jB DNA binding activity and reexpression of uPA. Further, we confirm that BRMS1 expression does not alter IKKb kinase activity suggesting that BRMS1-dependent uPA regulation does not occur through inhibition of the classical upstream activators of NF-jB. BRMS1 has been implicated as a corepressor of HDAC1 and consistent with this, we show that BRMS1 promotes HDAC1 recruitment to the NF-jB binding site of the uPA promoter and is associated with reduced H3 acetylation. We also confirm that BRMS1 expression stimulates disassociation of p65 from the NF-jB binding site of the uPA promoter consistent with its reduced DNA binding activity. These data suggest that BRMS1 recruits HDAC1 to the NF-jB binding site of the uPA promoter, modulates histone acetylation of p65 on the uPA promoter, leading to reduced NF-jB binding activity on its consensus sequence, and reduced transactivation of uPA expression.
Introduction
The molecular and biochemical mechanisms underlying cancer dissemination and metastasis remain poorly understood despite their obvious clinical importance. BRMS1 belongs to a growing number of metastasis suppressors that have the ability to suppress the metastatic potential of cancer cells in vivo without affecting tumorigenicity [1] [2] [3] . This diverse group of genes includes NM23, KAI1, MKK4, KiSS1 and BRMS1 among others [4] [5] [6] [7] [8] . The mechanism underlying metastasis suppression remains unknown for many of these genes. However, growing evidence suggests that metastasis suppressors may affect common signal transduction pathways including mitogen activated protein kinases, G-protein coupled receptors and tyrosine kinase receptors [3] . Recently we reported that BRMS1 suppressed uPA gene expression at least in part through the inhibition of NF-jB signaling in breast cancer and melanoma cells [9] . However the mechanisms underlying the suppression of uPA gene expression through NF-jB inhibition by BRMS1 remain to be elucidated. NF-jB is activated by a number of diverse signals, and the IKK complex (consisting of two related kinase subunits, IKKa and IKKb and the structural subunit IKKc) plays a key role in the cytokine-induced activation of latent NF-jB [10] [11] [12] [13] . Both IKKa and IKKb are required for cytokine-induced ubiquitination and degradation of the cytoplasmic inhibitors of NF-jB (IjBs) [14] and the phosphorylation and activation of the p65/RelA subunit of NF-jB that leads to the liberation and translocation of NFjB to the nucleus and subsequent activation of NF-jB responsive genes [15] .
In this study, we address how BRMS1 contributes to the suppression of NF-jB-dependent uPA expression in human C8161.9 melanoma cells stably expressing high levels of BRMS1 in independently derived cell lines. Interestingly we found that BRMS1 expression did not alter IKKb kinase activity suggesting that BRMS1 does not affect NFjB signaling through inhibition of the classical upstream activators of NF-jB in these cells. Furthermore, we show that BRMS1 recruits HDAC1 to the NF-jB consensus binding region of the uPA promoter using ChIP assays, and show reduced acetylation, suggesting that HDAC1 leads to H3 deacetylation and reduced binding of p65 at the NF-jB site of the uPA promoter. These findings reveal important novel insight into the potential mechanisms underlying the role of BRMS1 in metastasis suppression in C8161 melanoma cells.
Materials and methods

Cell culture
The amelanotic human melanoma cell line C8161 metastasizes to the lung when injected subcutaneously, intradermally or intravenously in nude mice [16] . The metastatic clone C8161.9 was obtained by limiting dilution cloning of parental C8161 cells [17] . C8161.9 cells and derivatives were grown in Dulbecco's Modified Eagle's Medium (DMEM) (GIBCO, Grand Island, NY) supplemented with 5% fetal calf serum, 1% L-glutamine and 1% penicillin and streptomycin, in 5% CO 2 and 95% air at 37°C. C8161.9 cells passage at 80-90% confluence using Ca 2? /Mg 2? -free PBS containing 2 mM EDTA. Full length, sequence verified, BRMS1-His cDNA was cloned into the mammalian constitutive expression vector pcDNA3 (Invitrogen, San Diego, CA) and stably transfected into parental C8161.9 cells by electroporation (GenePulser, Bio-Rad, Hercules, CA). Independently isolated G418-resistant transfectants (referred to as BRMS1-His2-1, BRMS1-His2-2, etc. or abbreviations of such in the text and Figures) were isolated and expanded and used in the experiments described. Controls for these experiments were independent transfectants expressing empty vector (C8161.9/pcDNA).
Electrophoretic mobility shift assay (EMSA) and NF-jB activation To determine the effect of BRMS1 expression on activation of NF-jB and other transcription factors, EMSA was performed as described previously [9] . For NF-jB binding activity, ten micrograms of nuclear protein were incubated at room temperature for 20 min with 32 P-end-labeled nucleotide derived from a NF-jB binding sequence (5 0 -AGT TGA GGG GAC TTT CCC AGG-3 0 ) from the immunoglobulin gene promoter. OCT-1 (5 0 -TGT CGA ATG CAA ATC ACT AGA A-3 0 ) transcription factor binding site oligonucleotides was obtained commercially (Santa Cruz Biotechnology, Santa Cruz, CA). The oligonucleotides for putative NF-jB sites on the uPA promoter were designed as follows: -1,849 to -1,833
and -782 to -774 (5 0 -TGG GAA GTT TCC ATA-3 0 ). The super-shift assay was performed with p65 and p50 antibodies in the NF-jB binding experiments. The complexes were resolved on 5% native polyacrylamide gels, which were dried and exposed to KODAK BioMax film at minus 80°C.
IKK activity assay
Kinase assays were performed as described previously [18] . Cells were washed once with phosphate-buffered saline and lysed and cellular debris was removed by centrifugation at 16,000 g for 15 min. For immunoprecipitations, cell extracts from C8161.9/pcDNA and C8161.9/BRMS1-His cells were incubated with 3 lg of total IKKc antibody for 4 h, followed by incubation for 1 h with 50 ll of protein ASepharose beads (50% suspension in dH 2 O). In vitro phosphorylation was performed using *1 lg of GSTIjBa substrate peptide (residues 1-54) with the immunoprecipitated IKKb as the kinase at 30°C for 30 min. Following the kinase reaction, phosphorylation of the GSTIjBa substrate was analyzed following SDS-PAGE and autoradiography. To determine the total amounts of IKKa, IKKb and IKKc in each sample, 40 lg of the whole-cell extract protein were resolved on a 7.5% acrylamide gel and then electroblotted onto a nitrocellulose membrane. The membrane was blocked with 5% nonfat milk protein for 1 h and incubated with anti-IKKa, anti-IKKb and anti-IKKc (1:1,000 dilution) (Cell Signaling Technology, Beverly, MA) for 1h. The membrane was washed and treated with horseradish peroxidase-conjugated secondary anti-mouse IgG antibody (Amersham Biosciences, Piscataway, NJ), and proteins were detected by chemiluminescence (Amersham Biosciences, Piscataway, NJ).
Real-time quantitative PCR amplification
Total RNA was isolated from C8161.9/pcDNA and C8161.9/BRMS1-His clones using the TRIzol method (Invitrogen, San Diego, CA). cDNA was synthesized from the RNA using SuperScript II reverse transcriptase according to vendor's instructions (Invitrogen, San Diego, CA). Oligonucleotide primers for real-time quantitative PCR (RTQ-PCR) of BRMS1, uPA, and GAPDH were designed using Primer Express v.1.5 (Applied Biosystems, Foster City, CA). Amplicons for each gene were designed to span introns to prevent contamination by genomic DNA. PCR conditions were set equal for BRMS1, uPA and GAPDH genes, using Syber Green PCR Core kit (Applied Biosystems, Foster City, CA) according to vendor instructions and an ABI 7900HT (Applied Biosystems, Foster City, CA) real-time PCR instrument. BRMS1 and uPA expression levels were calibrated using endogenous GAPDH expression levels [9] and confirmed with 18S as internal controls. Cycle conditions were: 95°C for 10 min (AmpliTaq Gold) followed by 45 cycles of 95°C for 15 s (denaturation) and 60°C for 60 s (annealing and extension) and fluorescence was quantified as a Ct value. The differences between the mean Ct values of BRMS1, uPA, and GAPDH were denoted (D-Ct) and the difference between DD-Ct and the D-Ct value of the GAPDH was calculated as DD-Ct. The log 2 (DD-Ct) gave the relative quantification value of expression. A single PCR amplified band was observed on ethidium bromide stained gels using standard PCR conditions for all genes. The following primers were used in the RTQ-PCR experiments: GAPDH (F):
Western blot analysis
Western blotting was performed as described previously [9] . Briefly, Proteins were separated on 12% SDS-PAGE gels. Blots were incubated with the primary antibodies specific to IjBa (Santa Cruz, CA), phospho IjBa, p38, phosphor p38, IKKa, IKKb and IKKc (Cell Signaling Technology, Inc, Beverly, MA), and uPA (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h. His antibody (Amersham Biosciences, Piscataway, NJ) specific to 69 His tag at C-terminus of BRMS1 was used to detect exogenous BRMS1-His expression. To monitor secreted uPA, cells were grown in serum free medium for 24 h. After this time, supernatant was concentrated 10-fold using Amicon ultra 10 K filters (Millipore, Bedford, MA) at 4,0009g for 30 min and analyzed by Western blot analysis using antibody specific for uPA. Actin was used as the loading control.
siRNA inhibition of BRMS1 expression in C8161.9/BRMS1-His clones Targeted interfering RNA (siRNA) oligonucleotides for BRMS1 (SmartPool) was purchased from Darmacon (Lafayette, CO). A mixture of siRNA duplexes were transiently transfected into C8161.9/pcDNA cells and C8161.9/BRMS1-His clones 2-4, 4-1 and 5-1 using LipofectAMINE 2000 (Invitrogen, San Diego, CA) according to the manufacturer's instructions. To optimize conditions, a dose response increasing concentrations of siBRMS1 oligonucleotide concentrations were used for each clone and the efficiency of inhibition of BRMS1 expression was confirmed by RTQ-PCR. Transient transfections of a range of concentrations of 0-50 nm siBRMS1 oligonucleotides were performed in OPTI-MEM media. After 72 h, nuclear and cytoplasmic proteins were extracted from siBRMS1-treated cells, and protein concentration quantified using PIERCE BCA protein assay (Pierce, Rockford, MA). For NF-jB binding activity, ten micrograms of nuclear protein were incubated at room temperature for 20 min with 32 P-end-labeled nucleotide derived from a NF-jB binding sequence as described above.
Chromatin immunoprecipitation (ChIP) Parental C8161.9 and BRMS1-His 2-4, BRMS1-His 4-1 and BRMS1-His 5-1 clones were fixed with 1% formaldehyde for 10 min and lysed in SDS lysis buffer (1% SDS, 10 mM EDTA, and 50 mM Tris-HCl, pH 8.1). The lysates were sonicated to reduce DNA fragments to 200-500 base pairs. The samples were precleared with protein A-agarose beads before Ab addition. 2 lg rabbit antibodies against human Acetylated H3, HDAC1 and p65 (all from Santa Cruz Biotechnology, Santa Cruz, CA) were added to the chromatin samples and incubated at 4°C overnight. We used rabbit IgG as a negative control. 40 ll of treated beads was then added to the chromatin samples and incubated at 4°C for 1 h. The beads were then washed three times and immunoprecipitated. The DNA fragments were then eluted after proteinase K treatment. DNA fragments were recovered by phenol/chloroform extraction. DNA was dissolved in 20 ll of TE buffer (10 mM Tris, 1 mM, pH 8.0). In immunoprecipitated samples, the NF-jB region in the uPA promoter was analyzed by RTQ-PCR. DD-Ct values are calculated as a ratio of immunoprecipitated 
Results
Previously, we demonstrated that the transcription factor NF-jB was constitutively activated in C8161.9 melanoma and MDA-MB-231 breast cancer cells, but was inhibited in C8161.9 and MDA-MB-231 cells stably expressing BRMS1 compared to parental cells [9] . To confirm these findings and to provide additional insight into mechanisms underlying BRMS1 suppression of NF-jB signaling, we now report the analysis of independently isolated C8161.9 cell lines stably expressing BRMS1-His for effects of BRMS1 expression on NF-jB signaling and HDAC1 recruitment and H3 deacetylation at the NF-jB binding site of the uPA promoter.
BRMS1 expression leads to the reduced expression of NF-jB regulated genes C8161.9 cells show high basal mRNA expression levels of the NF-jB regulated gene uPA and reduced levels of BRMS1 mRNA expression [9] . Consistent with our previous findings [9] , all independently isolated BRMS1-His clones in this study showed reduced NF-jB-dependent uPA mRNA and protein expression compared to C8161.9/ pcDNA (Fig. 1a, b) . Exogenous BRMS1-His expression was determined by RTQ-PCR using BRMS1-specific primers. The expression level of BRMS1-His in C8161.9/ BRMS-His clones ranged from 5.1 fold to 11.5 fold compared to parental C8161.9/pcDNA cells (Fig. 1a) . Relative BRMS1 protein expression was shown by anti-His antibody (Fig. 1b) . Only low levels of BRMS1 protein were detected suggesting a high turnover rate of BRMS1 protein in these cells. We also confirmed reduced protein expression of uPA in BRMS1-His expressing cells by Western blotting (Fig. 1b) . Translocation of the NF-jB p65/p50 heterodimer to the nucleus is mediated by IjBa phosphorylation and degradation. To better understand the mechanisms underlying BRMS1 inhibition of NF-jB signaling, we examined basal levels of IjBa phosphorylation and degradation in C8161.9/pcDNA and C8161.9/BRMS1-His clones. All C8161.9/BRMS1-His clones consistently showed reduced constitutive levels of IjBa phosphorylation compared to parental C8161.9/pcDNA cells (Fig. 2a) .
To better understand how BRMS1 may inhibit the NFjB pathway, we performed IKK kinase pull-down experiments. IKK kinase activity was based on phosphorylation of the IKK substrate, GST-IjBa, in C8161.9/pcDNA and BRMS1-His clones (Fig. 2b) . Basal IKK kinase activity was found at similar levels in parental and the majority of BRMS1-His clones, indicating that IKK kinase activity was not altered by BRMS1 expression. These data imply that BRMS1 does not modulate the upstream classical NF-jB pathway through IKKb. Although the basal level of IjBa phosphorylation is low in the transfectants, one should also expect to see low IKK kinase activity. That we do not see this may be due to cross-talk that may lead to repression of IjBa phosphorylation in the absence of changes in IKK activity. Further studies are needed to confirm this.
uPA is also regulated by MEKK1 which in turn regulates both the ERK1/2 and JNK signaling pathways [19, 20] . The p38 mitogen activated protein kinase (MAPK) pathway is also known to activate uPA expression in many cancer cell lines [19] . Published studies indicated that endogenous p38 MAPK activity increase invasiveness in breast cancer cells by increasing uPA/uPAR expression suggesting that p38 MAPK signaling pathway is involved in the regulation of uPA/uPAR expression [21] . We asked if this signaling pathway was altered by exogenous BRMS1 expression in C8161.9 cells. Our data show that activity of p38 MAPK (Fig. 2a) was not affected by BRMS1-His expression in all transfectants supporting to the fact that BRMS1 specifically represses NF-jB signaling.
The effect of BRMS1-His expression on NF-jB binding activity in C8161.9 cells was examined by EMSA using a 32 P-end-labeled oligonucleotide derived from a NF-jB consensus binding sequence [9] . While there was some variability in the reduction in constitutive NF-jB binding activity across C8161.9/BRMS1-His clones compared to C8161.9/pcDNA parental cells (Fig. 3 ) these data were consistent with our previous observation that BRMS1 expression negatively regulates NF-jB binding activity [9] . The effect of BRMS1 expression on the binding activity of transcriptional factor OCT-1 was also examined to determine if BRMS1 had a systematic effect on other transcriptional factors (Fig. 3) . BRMS1 had no effect on OCT-1 binding activity.
Inhibition of exogenous BRMS1 expression by siRNA leads to re-activation of NF-jB signaling To confirm that reduced NF-jB binding activity in BRMS1 expressing cells was the result of expression of BRMS1-His, we knocked down BRMS1 expression in 3 Fig. 2 a IjBa phosphorylation was inhibited by BRMS1 expression. Cytosolic protein fractions C8161.9/pcDNA, and corresponding BRMS1 clones were extracted from exponentially growing cells and analyzed by Western blot using antibodies specific for IjBa, phospho-IjBa (Ser 32 ), p38 and phospho-p38 in BRMS1-His clones. Equal protein loading was confirmed using b-actin antibody. IjBa phosphorylation was substantially reduced in BRMS1-expressing C8161.9 clones, however, phospho-p38 activity remained unaltered in BRMS1-His clones suggesting that BRMS1-His expression had no effect on MAPK signaling. b In vitro kinase activity was performed using *1 lg of GST-IjBa substrate peptide (residues 1-54) with the immunoprecipitated IKKa, IKKb as the kinase. Following the kinase reaction, phosphorylation of the GST-IjBa substrate was analyzed following SDS-PAGE and autoradiography. The ratio of kinase activity was determined by densitometric analysis using NIH ImageJ program. To determine the total amounts of IKKc, IKKa, IKKb in each sample, 40 lg of the whole-cell extract protein were resolved on a 7.5% acrylamide gel and then electroblotted onto a nitrocellulose membrane
independent clones expressing BRMS1 (BRMS1-His 2-4, BRMS1-His 4-1 and BRMS1-His 5-1) using siRNA. Optimal inhibition of BRMS1 was achieved for each clone using different concentrations (0-40 nM) of siBRMS1 oligonucleotides (Fig. 4a) . The vector control was not used in the siBRMS1 study because of low BRMS1 expression in these cells. siBRMS1 treatment did not affect OCT-1 binding activity (Fig. 4a) . Real-time PCR analyses demonstrated that BRMS1 inhibition by siRNA treatment led to re-expression of uPA (Fig. 4b ). There was a significant effect in transfectants BRMS1-His 2-3 and 4-1 but not His 5-1.
Reduced histone acetylation of the uPA promoter NFj-B binding region in C8161.9/BRMS1 cells To examine whether the observed BRMS1-dependent reduction in uPA expression was the direct result of HDAC1 targeting of the NF-jB binding region of the uPA promoter, ChIP assays were performed using antibodies against Ac-H3, HDAC1 and p65. The immunoprecipitated chromatin DNA fragments from parental and BRMS1 expressing clones were analyzed by RTQ-PCR of the NF-jB region of uPA promoter. There are four putative NF-kB binding regions in uPA promoter which were confirmed by supershift assay with p65 and p50 antibodies. We found that the sites between -1,849 and -1,812 have significant binding ability to NF-jB complex upon TNF-a treatment (Fig. 5a ). However the rest of the identified sites did not show specific binding to NF-kB. Our data show a reduced PCR amplification of the NF-jB binding region between -1,849 and -1,812 in Ac-H3 and p65 pull-down chromatin and an increased PCR amplification in the same region of uPA promoter in HDAC1 pull-down chromatin (Fig. 5b) in BRMS1-His 2-4, BRMS1-His 4-1 and BRMS1-His 5-1 clones. These results suggest that BRMS1 mediates HDAC1 recruitment to the NF-jB binding region of the uPA promoter and diminishes histone acetylation of this region.
Discussion
We previously demonstrated an inverse correlation between BRMS1 expression and NF-jB-dependent uPA gene expression in breast and melanoma cell lines [9] . In this study we confirm this observation in independently derived C8161 melanoma cells stably expressing BRMS1 and show modulation of its effect on uPA expression through siRNA knockdown studies of BRMS1. Importantly, we now demonstrate that BRMS1 potentially modulates NF-jB-dependent uPA gene expression by functioning as a HDAC1 corepressor of NF-jB-dependent gene transactivation. The underlying mechanism of NF-jB-dependent transcription regulation of uPA by BRMS1 remains to be elucidated. BRMS1 expression leads to the inhibition of IjBa phosphorylation and degradation, however, we confirm here that the BRMS1-dependent inhibition of NF-jB signaling occurs without affecting IKKb activity even though reduced basal levels of IjBa phosphorylation and degradation are observed. These data imply that BRMS1 regulated uPA gene expression through an IKKb-independent mechanism.
Mitogen activated protein kinase (MAPK) p38 has been reported to activate uPA expression in many cancer cell lines including breast cancer [19, 20] , suggesting that uPA expression could be regulated by MAPK signaling in BRMS1-expressing cells. However, we demonstrated that the phosphorylation level p38 was not altered by BRMS1 expression suggesting that BRMS1 may not involve MAPK signaling pathway.
There is recent evidence that BRMS1 plays a role in acetylation. BRMS1 has been shown to interact with the RBP/Sin3a transcriptional factor complex [22] [23] [24] , and studies have implicated BRMS1 in the repression of both basal and inducible p65 transactivation through recruitment as a corepressor for HDAC1 [25] . A direct interaction between BRMS1 and the ARID-4 transcriptional factor within the Sin3A/HDAC complex has been reported, however, disruption of binding between ARID-4 and BRMS1 did not change the metastatic suppression ability of BRMS1 [26] . Here, we demonstrate that BRMS1 significantly reduces NF-jB-dependent uPA expression in C8161 human melanoma cells by recruiting HDAC1 to the NF-jB site of the uPA promoter in association with deacetylation and reduced p65 levels. We found reduced levels of Ac-H3 and p65, but increased levels of HDAC1 associated with the NF-jB binding region of the uPA promoter in BRMS1 expressing cells using ChIP experiments. These data imply that BRMS1 is recruited to the uPA NF-jB promoter binding region where it acts as a HDAC1 corepressor leading to chromatin deacteylation of p65 and reduced transactivation by NF-jB.
Recent studies have suggested the importance of acteylation regulation in BRMS1-dependent gene regulation of NF-jB transactivation. The p65 subunit of NF-jB is acetylated by coactivators p300, CBP and p/CAF at several lysine residues with K310 playing the prominent role in p65 transcriptional regulation. BRMS1 was recently shown to abolish TNF-dependent acetylation of p65 on K310, resulting in a substantial decrease in p65 transactivation potential [25] . BRMS1 promoted HDAC1 binding to the RelA/p65 subunit of NF-jB where HDAC1 deacetylated lysine K310 on p65 at NF-jB binding sites of promoters of cIAP2 and Bfl-1/A1 leading to the loss of NF-jB-dependent transcriptional activation [25] . Interestingly, Samant et al. also recently showed that BRMS1 recruited HDAC3 to the NF-jB binding site of the OPN promoter in MDA-MB-435 breast cancer cells leading to deacetylation of p65 [27] , suggesting a complex role for BRMS1 in regulation of acetylation. Indeed, BRMS1 has been shown to interact with the RBP/Sin3a transcriptional factor complex [22] [23] [24] , and a role for this complex in BRMS1-dependent regulation of uPA cannot be ruled out.
In summary, we demonstrate that BRMS1 expression leads to the recruitment of HDAC1 to the NF-jB binding site of the uPA promoter and correlates with reduced acetylated H3 and dissociation of NF-jB from its consensus DNA sequence on the uPA promoter. These findings Fig. 4 a Activation of NF-jB binding by BRMS1 inhibition. In parallel, NF-jB activity was activated in corresponding clones with increasing siRNA concentration. OCT-1 binding activity was not changed following siBRMS1 treatment. Note that we did not use siBRMS1 treatment in parental clones to further knock-down BRMS1 expression because the expression levels of BRMS1 in these cells was low. Instead vector NF-kB activity was used as a control. The ratio of densitometric values siBRMS1 treatment was also determined by NIH suggest that BRMS1 regulates NF-jB-dependent transactivation of uPA at least in part through acting as a corepressor for HDAC1-meediated deacetylation of p65. We performed EMSA analysis with the NF-jB oligonucleotides labeled with 32 P using nuclear extracts prepared from exponentially growing C8161.9/pcDNA, treated with or without TNFa (20 ng/ml). Super-shift binding experiments were performed with p65 and p50 antibodies. b ChIP assays were performed in C8161.9/pCDNA and BRMS1-His 2-4, BRMS1-His 4-1 and BRMS1-His 5-1 transfectants using rabbit antibodies raised against human HDAC1, AcH3 and p65. We also used rabbit IgG as negative control. The NF-jB region in the uPA promoter was amplified by PCR using uPA promoter specific primers. Immunoprecipitated promoter fragments were analyzed by RTQ-PCR. Results are presented as a ratio of immunoprecipitated product to the input product. The input and rabbit IgG results were also presented as controls. Values are the mean of three repeats ±SE
